Sentence examples for trials were compared with from inspiring English sources

Efficacy results for particular statins obtained from placebo controlled trials were compared with those from trials using active comparators to determine comparability of results.

Statistical analysis was conducted in STATA 8. Dichotomous trial characteristics of African trials were compared with North American trials using univariate logistic regression.

Limitations in representativeness for the real-world diabetes care were found when HPS (DM) and CARDS trials were compared with population level data.

Conjunction 2 therefore identified brain areas that responded during subordinately biasing contexts and also when these trials were compared with conditions of lowest levels of semantic control (i.e., dominant contexts).

A subsequent conjunction analysis revealed that the left prefrontal and posterior temporal activations observed during subordinately biasing contexts were also present when these trials were compared with the least executively demanding condition (i.e., single-related dominant trials).

Math time and reaction time over the first 35 trials were compared with the second 35 trials at each of the above three blood glucose ranges: euglycemia (3.9 9.9 mmol/l), hypoglycemia (<3.0 mmol/l), and hyperglycemia (>22.2 mmol/l).

The results of the 2nd and 3rd trials are compared with outcomes of the 1st trial to determine how team size and information sharing system among sub-team members may affect the consequences, respectively.

For each subject, a 'planning versus baseline' main effect was computed in which brain activation during all planning trials was compared with brain activation during baseline trials.

For each guideline, the pooled odds ratio based on only the high-quality trials was compared with the odds ratio from meta-analysis of all trials that had been included originally in the review (Table 4).

More specifically, all patients treated in hospitals participating in clinical trials are compared with all patients treated in hospitals that did not participate in any clinical trials of the AGO-OVAR and NOGGO.

The dose patterns determined by the NCTPlan treatment planning system using the new THOR beam for a patient treated in the Harvard MIT clinical trial were compared with results of the MITR-II M67 beam.